Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Other Accumulated Expenses: 2015-2024

Historic Other Accumulated Expenses for Zevra Therapeutics (ZVRA) over the last 8 years, with Dec 2024 value amounting to $3.2 million.

  • Zevra Therapeutics' Other Accumulated Expenses rose 866.67% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year increase of 866.67%. This contributed to the annual value of $3.2 million for FY2024, which is 4.23% up from last year.
  • Per Zevra Therapeutics' latest filing, its Other Accumulated Expenses stood at $3.2 million for FY2024, which was up 4.23% from $3.1 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Other Accumulated Expenses registered a high of $3.2 million during FY2024, and its lowest value of $624,000 during FY2020.
  • Over the past 3 years, Zevra Therapeutics' median Other Accumulated Expenses value was $3.1 million (recorded in 2023), while the average stood at $2.3 million.
  • In the last 5 years, Zevra Therapeutics' Other Accumulated Expenses fell by 14.00% in 2022 and then skyrocketed by 326.98% in 2023.
  • Over the past 5 years, Zevra Therapeutics' Other Accumulated Expenses (Yearly) stood at $624,000 in 2020, then skyrocketed by 33.97% to $836,000 in 2021, then decreased by 14.00% to $719,000 in 2022, then soared by 326.98% to $3.1 million in 2023, then climbed by 4.23% to $3.2 million in 2024.